Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202507130 A Phase 1, Open-label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ZE46-0134 in Adults with FLT3 mutated or Spliceosome mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) New Medical Device NA
N202507134 A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER New Drug Phase Ⅲ
N202507135 EASi‑PROTKT™ -A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease New Drug Phase Ⅲ
N202507139 A Phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) New Drug Phase Ⅱ
N202507140 A Phase 1b/2 Open-Label, Multicenter Study of Zoldonrasib (RMC-9805) With or Without Daraxonrasib (RMC-6236), in Combination With Other Anticancer Agents, in Patients With RAS G12D-Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol C New Drug Phase Ⅲ
N202507150 A preliminary bioequivalence study to compare two zolpidem hemitartrate sublingual tablets in healthy subjects under fasted state. New Drug Phase Ⅲ
N202507153 A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants with Acute Suicidal Ideation or Behavior New Drug Phase Ⅲ
N202507154 An exploration of the optical characteristics of saliva and the relationship to oral diseases New Drug Phase Ⅰ
N202508002 A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater than or Equal to 50% (TroFuse-007) New Drug Phase Ⅰ
N202508013 A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate Efficacy and Safety of Mezagitamab (TAK-079) in Study Participants with Primary IgA Nephropathy in Combination with Stable Background Therapy New Drug Phase Ⅰ
1 2 8 9 10 11 12 13 14 31 32 / 32

TOP